Portfolio

BioSight

Advanced therapeutics

Technology Development

Business Development

Revenue

Exited

Founded

2000

CEO
Contact Us
Follow Us
linkedin
Investors

About

Trendlines’ shares in BioSight were acquired by Arkin Bio Ventures Ltd. in June 2017.

BioSight develops advanced therapeutics to enable safe and effective treatment for life-threatening diseases and to improve the quality of life for patients with cancer and related diseases.

BioSight’s pipeline of targeted chemotherapy pro-drugs target cancer cells and release active chemotherapy drugs inside the cancer cells while significantly minimizing the toxicity associated with conventional chemotherapy treatments.

Skip to content